Literature DB >> 26071044

Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.

L H Price1, R T Malison, C J McDougle, G H Pelton.   

Abstract

There is considerable interest in the possible antidepressant properties of antiglucocorticoids. Studies of the hypothalamic-pituitary-adrenal (HPA) axis in depression, coupled with increasing recognition of the importance of glucocorticoids in brain function, strongly support such interest.Psychiatric symptomatology in Cushing's syndrome (a disorder involving hypersecretion of cortisol), the adverse cognitive effects of glucocorticoids, and the suppressive effects of conventional antidepressants on HPA function all suggest that HPA abnormalities could cause or contribute to depression. However, the psychiatrie effects of glucocortieoids and glucocorticoid withdrawal suggest that HPA hyperactivity compensates for some other defect. While preliminary clinical studies suggest that both glucocorticoids and antiglucocorticoids may have efficacy in depression, the toxicity and loss of efficacy of available drugs during long term administration will probably necessitate the development of new agents to advance this field.

Entities:  

Year:  1996        PMID: 26071044     DOI: 10.2165/00023210-199605050-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  88 in total

1.  Increased glucocorticoid receptor gene promoter activity after antidepressant treatment.

Authors:  M C Pepin; M V Govindan; N Barden
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

2.  Cushing's syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome.

Authors:  M N Starkman; D E Schteingart; M A Schork
Journal:  Psychiatry Res       Date:  1986-11       Impact factor: 3.222

3.  Urinary free cortisol excretion in depression.

Authors:  B J Carroll; G C Curtis; B M Davies; J Mendels; A A Sugerman
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

Review 4.  Glucocorticoid-biogenic amine interactions in relation to mood and behavior.

Authors:  B S McEwen
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

5.  Metyrapone for depression and delirium secondary to Cushing's syndrome.

Authors:  K G Kramlinger; G C Peterson; P K Watson; L L Leonard
Journal:  Psychosomatics       Date:  1985-01       Impact factor: 2.386

6.  Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.

Authors:  L S Brady; H J Whitfield; R J Fox; P W Gold; M Herkenham
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 7.  Hypercortisolism and its possible neural bases.

Authors:  R M Sapolsky; P M Plotsky
Journal:  Biol Psychiatry       Date:  1990-05-01       Impact factor: 13.382

8.  Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature.

Authors:  D A Lewis; R E Smith
Journal:  J Affect Disord       Date:  1983-11       Impact factor: 4.839

9.  Prednisone effects on neurochemistry and behavior. Preliminary findings.

Authors:  O M Wolkowitz; D Rubinow; A R Doran; A Breier; W H Berrettini; M A Kling; D Pickar
Journal:  Arch Gen Psychiatry       Date:  1990-10

10.  The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

Authors:  A M Ghadirian; F Engelsmann; V Dhar; D Filipini; R Keller; G Chouinard; B E Murphy
Journal:  Biol Psychiatry       Date:  1995-03-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.